1. Medtech Insight
  2. >>Device Area

Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator

 
• By Reed Miller

The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.

stop the pain
• Source: Shutterstock

Nevro expects its new Senza HFX iQ to further differentiate the company’s spinal cord stimulation (SCS) technology from its competitors in the pain-relief neuromodulation market.

“[Senza HFX iQ] is the first and only big-data-[backed] spinal cord stimulation system, which is AI powered, and it's the only system that gets smarter over time by learning from...

Senza HFX iQ is the latest iteration of Nevro’s Senza high-frequency 10kHz (HFX) spinal cord stimulation technology.

In July 2021, Senza HFX became the first FDA-approved SCS...

More from Neurology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.